Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III randomized trial of gemcitabine + carboplatin versus mitomycin + ifosfamide + cisplatin in non-small cell lung cancer
ISRCTN52253218Phase 3Completed
- Sponsor
- London Lung Cancer Group
- Start
- Jan 1995
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
01
Overview
Phase 3, randomised, open-label trial of gemcitabine, carboplatin, mitomycin c, ifosfamide and cisplatin in non-small cell lung cancer (NSCLC) (2 arms), sponsored by London Lung Cancer Group. Started Jan 1995; status: completed.
02
Drugs
gemcitabinecarboplatinmitomycin cifosfamidecisplatin
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ISRCTN52253218.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN52253218.